… today,” said Christine Akinc, Alnylam’s chief corporate communications officer … Vertex did and Alnylam is doing. Alnylam is a pioneer in … genetic ailments. Arbuckle said he’s a longtime admirer of Alnylam … many patients as possible.” Alnylam so far has four …

… with conventional oligonucleotide manufacturing methods. Alnylam believes the investment will help … step as Alnylam’s research pipeline broadens beyond rare genetic diseases into … . From a technical perspective, Alnylam executives argue that innovations like …

… flagship manufacturing facility in Massachusetts. Alnylam plans to spend $250 million … “greatly” expand manufacturing capacity, which Alnylam argues makes “large-scale, sustainable … for producing RNAi and other genetic medicines drug substance requires joining …

… the heightened risk of genetic kidney conditions among South … more at risk of genetic kidney disease and how … professionals only. About Alnylam Pharmaceuticals Alnylam is a leading biopharmaceutical … and biotech leaders, Alnylam has translated the Nobel …

… to be true, certainly for genetically defined diseases.” In addition, Amvuttra … themselves from generic tafamidis. Alnylam has talked about tafamidis genericization … comparability pricing,” Foroohar noted. Alnylam is already experiencing slower-than …

… industry. Today, we’re featuring Alnylam Pharmaceuticals’ CSO, Kevin Fitzgerald, who … internal conviction. Fitzgerald, who joined Alnylam as associate director of research … polyneuropathy associated with the rare genetic disease hATTR amyloidosis, making good …

… donation from Alnylam Pharmaceuticals, the Phil Sharp-Alnylam Fund for … s key role at Alnylam.” Alnylam Pharmaceuticals, a company Sharp … as: What if the genetic drivers of diseases could … chief scientific officer of Alnylam Pharmaceuticals.  Today, the …

… Get to Know Alnylam Pharmaceuticals Better Alnylam Pharmaceuticals is a … across various therapeutic areas: genetic medicines; cardio-metabolic diseases; … commercialized under collaboration partnerships. Alnylam Pharmaceuticals: Delving into Financials …

… takes the company into genetic medicines. Chiesi Global Rare … genetic medicines do reduce oxalate levels, but they’re chronic therapies — Alnylam … in a lab and genetically engineered cells are infused … inside the patient. Its genetic cargo is encapsulated within …

… maintained its Outperform rating for Alnylam Pharmaceuticals, Inc. (NASDAQ … the firm believes that Alnylam Pharmaceuticals, Inc. (NASDAQ: … about $2.5 billion. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY … approved medications for rare genetic illnesses. While we …